May 14, 2019 / 03:40PM GMT
Michael Leonidovich Ryskin - BofA Merrill Lynch, Research Division - Associate
I think we'll get started. Hi, everyone. My name is Mike Ryskin. I'm from the life science tools and diagnostics team here at Bank of America Merrill Lynch. I want to welcome you to our health care conference. I'm here on behalf of Derik De Bruin, the senior analyst on the team. Unfortunately, he couldn't make it today. He's recovering from a recent surgery, but he's in New York and he's following the presentation on webcast. And believe me, he would be here if he could.
So here to start, we have Marc Casper, CEO of Thermo Fisher Scientific. Thank you for joining us, Marc. The format of the session will be a fireside chat, and then towards the end, I'll open it up to Q&A from the audience.
Questions and Answers:
Michael Leonidovich Ryskin - BofA Merrill Lynch, Research Division - AssociateSo to begin, I thought maybe we could just start with a quick overview of your first quarter results that you announced a few weeks ago. Certainly very robust on the top line,
Trustpilot
